In case you missed it: GPhC Joint statement on meeting regulatory standards during periods of global or national shortage of medicines
In July GPhC released a statement on the above:
"We are concerned to hear that people with Type 2 diabetes are experiencing problems accessing GLP-1 receptor agonists (GLP-1 RAs). We know that these are being widely prescribed for weight loss purposes and in some cases prescribed off-label.
We recognise the adverse impact that shortages and supply chain issues can have on patients, the public and wider health and care teams."
For the full statement and more information see GPhC website here.
|